Add links about new UK strain

Virology.org link courtesy de-facto
ljl-covid · Dec 20, 2020 · 01ebd74 · 01ebd74
1 parent 92b2c26
commit 01ebd74
Showing 1 changed file with 3 additions and 1 deletion.
diff --git a/README.md b/README.md
@@ -400,14 +400,16 @@ There is mixed advice on the use of masks by the general public, and the advice
 * Face masks to become mandatory in shops in [England](https://www.bbc.com/news/uk-politics-53397617) and [France](https://www.france24.com/en/20200714-macron-wearing-masks-in-enclosed-public-spaces-to-become-mandatory-in-france), while [CDC study recommends mask mandates to battle coronavirus](https://www.cnbc.com/2020/07/14/cdc-study-says-mask-mandates-should-be-considered-after-examining-missouri-hair-salon.html), claiming it could get it [under control in one to two months if everyone wears a mask](https://www.cnbc.com/2020/07/14/cdc-says-us-could-get-coronavirus-under-control-in-one-to-two-months-if-everyone-wears-a-mask.html)
 * [Experimental COVID-19 vaccine safe, generates immune response](https://www.nih.gov/news-events/news-releases/experimental-covid-19-vaccine-safe-generates-immune-response) in the NIH-sponsored Phase 1 trial tested mRNA vaccine co-developed with Moderna
 * [Denmark to restrict North Jutland borders due to mink coronavirus outbreak](https://www.thelocal.dk/20201105/denmark-to-restrict-north-jutland-borders-due-to-mink-coronavirus-outbreak) from [a mutated strain that may be less susceptible to current antibodies or vaccines](https://blogs.sciencemag.org/pipeline/archives/2020/11/05/dont-make-mine-mink)
-* [SARS-CoV-2 spike mutations arising in Danish minkand their spread to humans], preliminary paper by the Danish Statens Serum Institut on the mink strains and human spill-back, following an earlier [WHO statement on the matter](https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/) and later a [risk assessment paper by the ECDC](https://www.ecdc.europa.eu/en/publications-data/detection-new-sars-cov-2-variants-mink)
+* [SARS-CoV-2 spike mutations arising in Danish mink and their spread to humans], preliminary paper by the Danish Statens Serum Institut on the mink strains and human spill-back, following an earlier [WHO statement on the matter](https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/) and later a [risk assessment paper by the ECDC](https://www.ecdc.europa.eu/en/publications-data/detection-new-sars-cov-2-variants-mink)
+* [COG-UK update on SARS-CoV-2 Spike mutations of special interest](https://www.cogconsortium.uk/wp-content/uploads/2020/12/Report-1_COG-UK_19-December-2020_SARS-CoV-2-Mutations.pdf) comes after the [UK government announces a mutation](https://www.reuters.com/article/uk-health-coronavirus-britain-strain/uk-says-new-coronavirus-strain-is-more-infectious-but-vaccines-should-still-work-idUSKBN28T0KL) gaining prevalence in South-East England, including London, which appears to spread more easily than pre-existing ones, as also shown in a [Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)
 * [Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against) in a press release where they state that their BNT162b2 vaccine has more than 90% efficacy, based on 94 participant who got COVID-19 during the trial, without any serious safety concerns; the article [Vaccine Efficacy Data!](https://blogs.sciencemag.org/pipeline/archives/2020/11/09/vaccine-efficacy-data) by Derek Lowe provides an early opinion on these results
 * [Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study](https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy), announces the company in a press release claiming a first interim analysis of 95 COVID cases showed an efficacy of 94.5% for their mRNA-1273 vaccine, and severe cases only in the control arm, during their [COVE Phase 3 trial](https://www.modernatx.com/cove-study)
 * [Oxford University](https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine) and [AstraZeneca](https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222hlr.html) both issue press releases on interim efficacy assessment of their ChAdOx1 nCoV-2019 vaccine, showing overall 70% efficacy but divided into 62% for a group that received two full doses, and 90% for a group receiving a half dose followed by a full-dose booster, and Derek Lowe discusses these results and the methodological differences compared to Pfizer and Moderna in [Oxford/AZ Vaccine Efficacy Data](https://blogs.sciencemag.org/pipeline/archives/2020/11/23/oxford-az-vaccine-efficacy-data)
 * [Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose](https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/), as announced by Gamaleya in a press release, where it was also specified that no significant adverse reactions have occurred; the international price for this vaccine was stated as being below $10
 * [Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization](https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study) in a press release where efficacy is put at 94.1%, with 100% efficacy against "severe" cases, after 196 COVID cases have developed within the trial participants, and after more than two months of follow-up
 * [The Wuhan files — Leaked documents reveal China's mishandling of the early stages of Covid-19](https://edition.cnn.com/2020/11/30/asia/wuhan-china-covid-intl/index.html) is a CNN release of excerpts of private documents from the Chinese government supposedly showing cover-ups of facts about the epidemic, including a 20-fold increase of what was thought to be influenza in Hubei during December 2019
 * [Pfizer-BioNTech COVID-19 vaccine and related biological product advisory committee briefing document](https://www.fda.gov/media/144246/download) announces that this vaccine meets the FDA success criteria, with vaccine efficacy after the booster dose at 95.0%, counting 8 COVID-19 cases in the vaccine group compared to 162 COVID-19 cases in the placebo group, with a 95% credible interval of 90.3% to 97.6%
+* [UK says new coronavirus strain is more infectious, but vaccines should still work](https://www.reuters.com/article/uk-health-coronavirus-britain-strain/uk-says-new-coronavirus-strain-is-more-infectious-but-vaccines-should-still-work-idUSKBN28T0KL) is also covered in [Britain says new coronavirus variant up to 70% more transmissible](https://www.straitstimes.com/world/europe/britain-says-new-coronavirus-variant-up-to-70-more-transmissible), a quick fact sheet by The Straits Times
 
 ## API and feeds